Lantheus Completes Acquisition of Evergreen Theragnostics
Lantheus Holdings (NASDAQ: LNTH) has completed its acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, as announced on January 28, 2025. The acquisition brings key assets to Lantheus including:
- OCTEVY™, a registrational-stage PET diagnostic imaging agent for neuroendocrine tumors, complementing Lantheus' therapeutic candidate PNT2003
- A portfolio of clinical and pre-clinical theranostic pairs
- Radioligand therapy manufacturing infrastructure
- A revenue-generating CDMO business
The strategic move strengthens Lantheus' position in the radiopharmaceutical sector by expanding its capabilities across development, manufacturing, and commercialization.
Lantheus Holdings (NASDAQ: LNTH) ha completato l'acquisizione di Evergreen Theragnostics, un'azienda di radiopharmaceuticals in fase clinica, come annunciato il 28 gennaio 2025. L'acquisizione porta a Lantheus asset chiave tra cui:
- OCTEVY™, un agente di imaging diagnostico PET in fase registrativa per tumori neuroendocrini, che completa il candidato terapeutico di Lantheus PNT2003
- Un portafoglio di coppie teranostiche cliniche e pre-cliniche
- Infrastruttura per la produzione di terapie radioligandiche
- Un'attività CDMO generatrice di entrate
Questa mossa strategica rafforza la posizione di Lantheus nel settore dei radiopharmaceuticals ampliando le sue capacità nello sviluppo, nella produzione e nella commercializzazione.
Lantheus Holdings (NASDAQ: LNTH) ha completado su adquisición de Evergreen Theragnostics, una empresa de radiofármacos en etapa clínica, como se anunció el 28 de enero de 2025. La adquisición aporta activos clave a Lantheus, incluyendo:
- OCTEVY™, un agente de imagenología diagnóstica PET en etapa de registro para tumores neuroendocrinos, que complementa el candidato terapéutico de Lantheus PNT2003
- Un portafolio de pares teranósticos clínicos y preclínicos
- Infraestructura para la fabricación de terapia con radioligandos
- Un negocio CDMO generador de ingresos
Este movimiento estratégico refuerza la posición de Lantheus en el sector de los radiofármacos al ampliar sus capacidades en desarrollo, fabricación y comercialización.
란시어스 홀딩스 (NASDAQ: LNTH)가 에버그린 테라그노스틱스라는 임상 단계의 방사선 의약품 회사를 2025년 1월 28일 발표한 대로 인수 완료했습니다. 이번 인수로 란시어스는 다음과 같은 주요 자산을 확보하게 되었습니다:
- OCTEVY™, 신경내분비 종양을 위한 등록 단계의 PET 진단 이미징 제제, 란시어스의 치료 후보 PNT2003을 보완합니다.
- 임상 및 전임상 테라노스틱 쌍의 포트폴리오
- 방사성 리간드 치료 제조 인프라
- 수익을 창출하는 CDMO 사업
이번 전략적 결정은 개발, 제조 및 상업화 전반에 걸쳐 란시어스의 역량을 확장하여 방사선 의약품 분야에서의 입지를 강화합니다.
Lantheus Holdings (NASDAQ: LNTH) a finalisé l'acquisition de Evergreen Theragnostics, une entreprise de radiopharmaceutiques en phase clinique, comme annoncé le 28 janvier 2025. L'acquisition apporte des actifs clés à Lantheus, notamment :
- OCTEVY™, un agent d'imagerie diagnostique PET en phase d'enregistrement pour les tumeurs neuroendocrines, complétant le candidat thérapeutique PNT2003 de Lantheus
- Un portefeuille de paires théranostiques cliniques et précliniques
- Infrastructure de fabrication pour la thérapie par radioligands
- Une activité CDMO génératrice de revenus
Ce mouvement stratégique renforce la position de Lantheus dans le secteur des radiopharmaceutiques en élargissant ses capacités en matière de développement, de fabrication et de commercialisation.
Lantheus Holdings (NASDAQ: LNTH) hat die Übernahme von Evergreen Theragnostics, einem Unternehmen für radiopharmazeutische Produkte in der klinischen Phase, abgeschlossen, wie am 28. Januar 2025 bekannt gegeben wurde. Die Übernahme bringt wichtige Vermögenswerte zu Lantheus, darunter:
- OCTEVY™, ein PET-Diagnosebildgebungsagent in der Registrierungsphase für neuroendokrine Tumoren, der den therapeutischen Kandidaten PNT2003 von Lantheus ergänzt
- Ein Portfolio klinischer und präklinischer theranostischer Paare
- Infrastruktur zur Herstellung von Radioligandtherapien
- Ein umsatzgenerierendes CDMO-Geschäft
Dieser strategische Schritt stärkt die Position von Lantheus im Bereich der Radiopharmazeutika, indem er die Fähigkeiten in der Entwicklung, Herstellung und Vermarktung erweitert.
- Acquisition of revenue-generating CDMO business provides immediate revenue stream
- Enhanced manufacturing capabilities across radiopharmaceutical value chain
- Strategic addition of OCTEVY™ diagnostic agent complements existing therapeutic candidate
- Expanded portfolio with clinical and pre-clinical theranostic pairs
- None.
BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. (“Evergreen”), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025.
Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate PNT2003, as well as a portfolio of clinical and pre-clinical theranostic pairs. The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.
“Today marks a significant milestone in our journey to expand our radiopharmaceutical leadership and we’re excited to welcome Evergreen’s talented team to Lantheus,” said Brian Markison, CEO of Lantheus. “By acquiring Evergreen Theragnostics, we are enhancing Lantheus’ capabilities across the entire radiopharmaceutical value chain, from development to manufacturing to commercialization. With Evergreen’s scalable manufacturing infrastructure and expertise as well as its promising pipeline of oncology-focused assets, including OCTEVY, we are better positioned than ever to meet the complex demands of the market. We look forward to integrating Evergreen’s capabilities to drive innovation and deliver better outcomes for patients worldwide.”
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
About Evergreen Theragnostics, Inc.
Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary products. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing, research, and clinical development. For more information, please visit www.evergreentgn.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "continue,” “may,” “poised,” “potential,” “will,” and other similar terms and include, among other things, statements about the potential benefits and results of the acquisition; the potential regulatory approval of OCTEVYTM; the potential for OCTEVYTM and PNT2003 to be used as a theranostic pair; and Evergreen’s ability to generate novel radiotherapeutic programs. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: risks related to diverting the attention of Evergreen’s and Lantheus’ management from ongoing business operations; failure to realize the expected benefits of the acquisition; significant transaction costs and/or unknown or inestimable liabilities; the risk that Evergreen’s business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the uncertainty of expected future regulatory filings, financial performance and results of the combined company following completion of the acquisition; pharmaceutical product development and the uncertainty of clinical success; the regulatory approval process, including the risks that we may be unable to obtain regulatory approval for OCTEVYTM on the timeframe anticipated, or at all, or that we may be unable to obtain regulatory approvals of any of our other product candidates in a timely manner or at all; disruption from the proposed acquisition, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; effects relating to the announcement of the consummation of the acquisition on the market price of Lantheus’ common stock; the possibility that, if Lantheus does not achieve the perceived benefits of the acquisition as rapidly or to the extent anticipated by financial analysts or investors, the market price of Lantheus’ common stock could decline; potential litigation associated with the acquisition; and the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q).
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
FAQ
What key assets did Lantheus (LNTH) acquire from Evergreen Theragnostics in April 2025?
How does OCTEVY™ complement Lantheus' existing portfolio?
What manufacturing capabilities did Lantheus gain through the Evergreen acquisition?
When was the Evergreen Theragnostics acquisition by Lantheus (LNTH) first announced?
